Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...

On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The company says the data ...

On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The company says the data are ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Investing.com -- Shares of Third Harmonic (NASDAQ:HLIT) Bio, Inc. (NASDAQ:THRD) plummeted 35% following the announcement of Phase 1 clinical trial results for its drug candidate THB335 and a strategic ...

Third Harmonic (NASDAQ:HLIT) Bio, Inc. (THRD) has experienced a notable downturn, touching a 52-week low of $5.58. This latest price point reflects a significant ...